FINAL EXAM
NATIONAL BOARD OF EXAMINATIONS
JUNE 2020
NEUROLOGY
PAPER-II
NEURO/J/20/23/III
Max. Marks:100
Important Instructions:
Attempt al questions in order.
Read the question careful y and answer to the point neatly and legibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer al the parts of a single question together.
Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
1. Classification of genetic dystonias.
10
10
3. Monoclonal antibodies in migraine.
10
4. Neurological complications of renal failure.
5. Discuss evaluation and management of non-motor manifestations of
10
parkinson's disease.
6. Role of monoclonal antibodies in multiple sclerosis.
7. Newer oral anticoagulants (NOACS) and stroke.
10
8. Recent advances in the management of SMA.
10
10
10. Role of neuromodulation in neurological disorders.
10
************
EXAMINATION HALL.
NATIONAL BOARD OF EXAMINATIONS
JUNE 2020
NEUROLOGY
PAPER-II
--- Content provided by FirstRanker.com ---
Time: 3 hoursNEURO/J/20/23/III
Max. Marks:100
Important Instructions:
Attempt al questions in order.
--- Content provided by FirstRanker.com ---
Each question carries 10 marks.Read the question careful y and answer to the point neatly and legibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer al the parts of a single question together.
--- Content provided by FirstRanker.com ---
Start the answer to a question on a fresh page or leave adequate space between two answers.Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
1. Classification of genetic dystonias.
10
--- Content provided by FirstRanker.com ---
2. Antisense oligonucleotides in neurology.10
3. Monoclonal antibodies in migraine.
10
4. Neurological complications of renal failure.
--- Content provided by FirstRanker.com ---
105. Discuss evaluation and management of non-motor manifestations of
10
parkinson's disease.
6. Role of monoclonal antibodies in multiple sclerosis.
--- Content provided by FirstRanker.com ---
107. Newer oral anticoagulants (NOACS) and stroke.
10
8. Recent advances in the management of SMA.
10
--- Content provided by FirstRanker.com ---
9. Management of acute ischaemic stroke beyond 4.5 hrs from onset.10
10. Role of neuromodulation in neurological disorders.
10
************
--- Content provided by FirstRanker.com ---
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THEEXAMINATION HALL.